It has been demonstrated that a combination of emodin (20 μM) and sorafenib (2 μM) has an additive effect to inhibit tumor growth through decreasing AKT and STAT3 oncogenic growth signaling in mice model xenografted with HCC cells (HepG2 or SK-HEP-1) [143]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.